Arbutus Biopharma (ABUS) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed MiMedx Group (MDXG) over the past year, gaining 0.0% versus a loss of 36.5%. Over five years, ABUS leads with a +5.1% price change compared with -31.8% for MDXG. MiMedx Group is the larger company by market cap ($670.6 million vs $644.5 million), about 1.0 times the size.
On valuation, Arbutus Biopharma trades at a lower trailing P/E (5.3x vs 114.9x for MiMedx Group).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | MDXG |
|---|---|---|
| Share price | $4.21 | $4.60 |
| Market cap | $644.53M | $670.57M |
| 1-day change | -1.98% | -0.33% |
| YTD return | -10.81% | -31.91% |
| 1-year return | 0.00% | -36.50% |
| 5-year return | +5.15% | -31.80% |
| P/E ratio (TTM) | 5.32 | 114.88 |
| Forward P/E | — | 22.97 |
| EPS (TTM) | $0.79 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $7.97 |
| 52-week low | $3.50 | $3.03 |
| Distance from 52-week high | -22.84% | -42.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +27.23% | +61.04% |
| Average volume | 4.68M | 1.23M |
| Shares outstanding | 153.28M | 145.93M |
| Employees | 19 | 808 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed MDXG by 36.5 percentage points over the past year.
- MiMedx Group trades at a higher earnings multiple (114.9x vs 5.3x trailing P/E).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
ABUS vs MDXG FAQ
Which is bigger, Arbutus Biopharma or MiMedx Group?
MiMedx Group (MDXG) is larger, with a market capitalization of $670.57M compared with $644.53M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or MDXG?
ABUS returned 0.00% over the past 12 months, compared with -36.50% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABUS or MDXG?
ABUS has the lower trailing P/E at 5.3, versus 114.9 for MDXG. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and MiMedx Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arbutus Biopharma and Medical/Dental Instruments for MiMedx Group.